WITHDRAWN: Hyaluronate for temporomandibular joint disorders.

Cochrane Database Syst Rev

Department of Oral and Maxillofacial Surgery, State Key Laboratory of Oral Diseases, West China College of Stomatology, Sichuan University, No. 14, Section Three, Ren Min Nan Road, Chengdu, Sichuan, China, 610041.

Published: October 2013

This review has been withdrawn from publication because it is out of date and does not meet the current methodological standards of The Cochrane Collaboration. The editorial group responsible for this previously published document have withdrawn it from publication.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687498PMC
http://dx.doi.org/10.1002/14651858.CD002970.pub2DOI Listing

Publication Analysis

Top Keywords

withdrawn publication
8
withdrawn hyaluronate
4
hyaluronate temporomandibular
4
temporomandibular joint
4
joint disorders
4
disorders review
4
review withdrawn
4
publication meet
4
meet current
4
current methodological
4

Similar Publications

Introduction: The use of weight loss supplements is increasing, often driven by online marketing. However, many of these supplements are adulterated with undeclared pharmaceutical substances, potentially posing significant health risks. We investigated the presence of sibutramine and sildenafil in weight loss supplements and assessed the associated clinical outcomes.

View Article and Find Full Text PDF

Background: Preclinical studies and anecdotal case reports support the potential therapeutic benefit of low-dose oral ketamine as a treatment of clinical symptoms in Rett syndrome (RTT); however, no controlled studies have been conducted in RTT to evaluate safety, tolerability and efficacy.

Design: This was a sequentially initiated, dose-escalating cohort, placebo-controlled, double blind, randomized sequence, cross-over study of oral ketamine in 6-12-year-old girls with RTT to evaluate short-term safety and tolerability and explore efficacy.

Methods: Participants were randomized to either five days treatment with oral ketamine or matched placebo, followed by a nine-day wash-out period and then crossed-over to the opposite treatment.

View Article and Find Full Text PDF

Targeting Kv7 Potassium Channels for Epilepsy.

CNS Drugs

January 2025

Division of Pharmacology, Department of Neuroscience, University of Naples "Federico II", Naples, Italy.

Voltage-gated Kv7 potassium channels, particularly Kv7.2 and Kv.7.

View Article and Find Full Text PDF

Background and objectives The persistent nature of diabetic foot ulcers (DFUs) is mainly attributable to compromised wound healing mechanisms, which are aggravated due to poor blood flow, neuropathy, and infection. Growth factors have become essential agents in the treatment of DFUs, serving as primary mediators that enhance wound healing through the stimulation of cell proliferation, migration, and angiogenesis. This prospective open-label, randomised, comparative, multi-centre, investigator-initiated study compared the safety and effectiveness of adjuvant therapy with topical application of autologous growth factor concentrate (AGFC) using the Healrex therapy kit (Wockhardt, India) versus standard of care (SoC) in DFUs.

View Article and Find Full Text PDF

Evaluation of the serum level of Lipocalin 2 in vitiligo.

Arch Dermatol Res

January 2025

Department of Dermatology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.

Vitiligo is considered as depigmenting skin disorder where patches of skin losing their pigment. Lipocalin-2 (LCN2) is one of the Inflammatory adipokines that has a potential role in skin disorders and other inflammatory diseases as well. To measure the concentration level of LCN2 in vitiligo patients compared to healthy controls and to investigate its relation to disease activity and other clinical data to evaluate its role in the pathogenesis of the disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!